The invention relates to an improved method for immunotherapy of cancer by
administering to a subject a human anti-hCG monoclonal antibody and/or an
hCG immunogenic peptide vaccine, followed by monitoring the patient's
immune response to hCG-CTP16, hCG-CTP21 and hCG-CTP37, respectively, and
adjusting the vaccination regimen according to the detectable immune
response to the hCG immunogenic peptides. The invention further relates to
devices, methods and kits for immunoassay of hCG immunogenic peptides.
